Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""hand-foot syndrome"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 2244
Tytuł:
A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Autorzy:
Huang W; Department of Medical Oncology, Fujian Medical University Union Hospital, No.29, Xinquan Road, Gulou District, Fuzhou, Fujian province, 350001, China.; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.; Fujian Key Laboratory of Translational Cancer Medicine, Fujian Cancer Hospotial, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Wang C; Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Fujian Normal University Qishan Campus, College Town, Fuzhou, Fujian Province, 350117, PR China.
Shen Y; Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Fujian Normal University Qishan Campus, College Town, Fuzhou, Fujian Province, 350117, PR China.
Chen Q; Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, Fujian Normal University Qishan Campus, College Town, Fuzhou, Fujian Province, 350117, PR China.
Huang Z; Department of Breast Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Liu J; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Lin X; Department of Medical Oncology, Fujian Medical University Union Hospital, No.29, Xinquan Road, Gulou District, Fuzhou, Fujian province, 350001, China. .; Fujian Key Laboratory of Translational Cancer Medicine, Fujian Cancer Hospotial, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China. .
Wang L; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Wu F; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Chen X; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Li N; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Hong Y; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Chen M; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Li J; Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Huang C; Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.91, Fuma Road, Jin'an District, Fuzhou, Fujian province, 350014, China.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 05; Vol. 24 (1), pp. 39. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/drug therapy
Hand-Foot Syndrome*
Hypertension*
Leukopenia*
Humans ; Clinical Protocols
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
[Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Autorzy:
Yan Q; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Yao WT; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Du XH; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Guo LY; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Fan YC; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2023 Oct 23; Vol. 45 (10), pp. 904-910.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Hand-Foot Syndrome*
Sarcoma*/drug therapy
Sarcoma, Synovial*/drug therapy
Soft Tissue Neoplasms*
Bone Neoplasms*
Humans ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A case of hand-foot syndrome with olaparib.
Autorzy:
da Costa REAR; Health Science Center, State University of Piauí, Teresina (PI), Brazil.
Valença RJV; Health Science Center, State University of Piauí, Teresina (PI), Brazil.
Pokaż więcej
Źródło:
The Pan African medical journal [Pan Afr Med J] 2022 Dec 30; Vol. 43, pp. 216. Date of Electronic Publication: 2022 Dec 30 (Print Publication: 2022).
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Hand-Foot Syndrome*/diagnosis
Hand-Foot Syndrome*/etiology
Humans ; Phthalazines/adverse effects ; Piperazines/adverse effects ; Hand
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Autorzy:
Kao YS; Department of Radiation Oncology, China Medical University Hospital, Taichung City, Taiwan.
Lo CH; Department of Pharmacy, Evergreen General Hospital, Taoyuan City, Taiwan.
Tu YK; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.; Department of Dentistry, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan.
Hung CH; Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua City, Taiwan.
Pokaż więcej
Źródło:
Dermatologic therapy [Dermatol Ther] 2022 Oct; Vol. 35 (10), pp. e15774. Date of Electronic Publication: 2022 Aug 30.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Hand-Foot Syndrome*/drug therapy
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Silymarin*
Antimetabolites, Antineoplastic/adverse effects ; Capecitabine/adverse effects ; Celecoxib ; Humans ; Network Meta-Analysis ; Pyridoxine/therapeutic use ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Autorzy:
Zou, Jiayun (AUTHOR)
Wang, Yuanyuan (AUTHOR)
Xu, Jiayu (AUTHOR)
Li, Jinna (AUTHOR)
Wang, Tianzhuo (AUTHOR)
Zhang, Ying (AUTHOR)
Bai, Yibo (AUTHOR)
Pokaż więcej
Źródło:
Journal of Clinical Medicine. Jan2024, Vol. 13 Issue 1, p57. 14p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
Autorzy:
Fang, Yu (AUTHOR)
Su, Ning (AUTHOR)
Zou, Qihua (AUTHOR)
Cao, Yi (AUTHOR)
Xia, Yi (AUTHOR)
Tang, Linquan (AUTHOR)
Tian, Xiaopeng (AUTHOR)
Liu, Panpan (AUTHOR)
Cai, Qingqing (AUTHOR)
Pokaż więcej
Źródło:
BMC Medicine. 11/7/2023, Vol. 21 Issue 1, p1-10. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Autorzy:
Iimura Y; Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. .
Furukawa N; Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Ishibashi M; Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Ahiko Y; Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.; The Department of Surgery, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Tanabe T; Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.; The Department of Surgery, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Aikou S; Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.; The Department of Surgery, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Shida D; Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.; The Department of Surgery, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Nojima M; Center for Translational Research, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Kuroda S; Department of Pharmacy, The IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Boku N; Department of Oncology and General Medicine, The Institute of Medical Science Hospital, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2022 Jul 14; Vol. 22 (1), pp. 341. Date of Electronic Publication: 2022 Jul 14.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Colorectal Neoplasms*/etiology
Hand-Foot Syndrome*/drug therapy
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine/adverse effects ; Chemotherapy, Adjuvant/adverse effects ; Clinical Trials, Phase II as Topic ; Fluorouracil/adverse effects ; Humans ; Hydrocortisone/therapeutic use ; Oxaliplatin/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical.
Autorzy:
Elyasi S; Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medical Sciences, Mashhad, Iran.; Associate Professor of Clinical Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Rasta S; Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Radiotherapy Oncologist, Mashhad University of Medical Sciences, Mashhad, Iran.
Taghizadeh-Kermani A; Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Associate Professor of Radio-Oncology, Mashhad University of Medical Sciences, Mashhad, Iran.
Hosseini S; Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. .
Pokaż więcej
Źródło:
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2022 Jun; Vol. 30 (1), pp. 117-125. Date of Electronic Publication: 2022 Mar 23.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Breast Neoplasms*/drug therapy
Curcumin*
Hand-Foot Syndrome*/drug therapy
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Lawsonia Plant*
Antimetabolites, Antineoplastic/therapeutic use ; Capecitabine/adverse effects ; Female ; Humans ; Ointments/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Autorzy:
Santhosh A; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Kumar A; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Pramanik R; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Gogia A; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Prasad CP; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Gupta I; Department of Biotechnology, Indian Institute of Technology, New Delhi, India.
Gupta N; Department of Oncoanesthesia and Palliative Care, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Cheung WY; Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Canada.
Pandey RM; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Batra A; Department of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India. .
Pokaż więcej
Źródło:
Trials [Trials] 2022 May 19; Vol. 23 (1), pp. 420. Date of Electronic Publication: 2022 May 19.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Hand-Foot Syndrome*/diagnosis
Hand-Foot Syndrome*/etiology
Hand-Foot Syndrome*/prevention & control
Antimetabolites, Antineoplastic ; Capecitabine/adverse effects ; Celecoxib/therapeutic use ; Cyclooxygenase 2 Inhibitors/therapeutic use ; Diclofenac/adverse effects ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review.
Autorzy:
Zaiem A; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Hammamia SB; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Aouinti I; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Charfi O; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Ladhari W; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Kastalli S; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Aidli SE; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Lakhoua G; Department of Collection and Analysis of Adverse Drug Events, National Center Chalbi Belkahia of Pharmacovigilance; Research Unit UR17ES12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Pokaż więcej
Źródło:
Indian journal of pharmacology [Indian J Pharmacol] 2022 May-Jun; Vol. 54 (3), pp. 208-215.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hand-Foot Syndrome*/epidemiology
Hand-Foot Syndrome*/etiology
Erythema/chemically induced ; Erythema/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Quality of Life ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
Autorzy:
Jiang Y; University of Michigan School of Nursing, Ann Arbor, MI, USA. .; Department of Systems, Populations, and Leadership, University of Michigan School of Nursing, 400 North Ingalls Building, Room 4160, Ann Arbor, MI, 48109, USA. .
Mason M; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Cho Y; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Chittiprolu A; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Zhang X; Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Harden K; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Gong Y; The University of Texas Health Science Center at Houston School of Biomedical Informatics, Houston, TX, USA.
Harris MR; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Barton DL; University of Michigan School of Nursing, Ann Arbor, MI, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Sep 03; Vol. 22 (1), pp. 950. Date of Electronic Publication: 2022 Sep 03.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Breast Neoplasms*/drug therapy
Drug-Related Side Effects and Adverse Reactions*
Hand-Foot Syndrome*
Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Capecitabine/adverse effects ; Electronic Health Records ; Fatigue/chemically induced ; Female ; Fluorouracil/therapeutic use ; Humans ; Patient Reported Outcome Measures ; Pilot Projects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification of hand-foot syndrome from cancer patients' blog posts: BERT-based deep-learning approach to detect potential adverse drug reaction symptoms.
Autorzy:
Nishioka S; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Watanabe T; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Asano M; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Yamamoto T; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Kawakami K; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yada S; Nara Institute of Science and Technology, Nara, Japan.
Aramaki E; Nara Institute of Science and Technology, Nara, Japan.
Yajima H; Mediaid Corporation, Tokyo, Japan.
Kizaki H; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Hori S; Keio University Faculty of Pharmacy, Division of Drug Informatics, Tokyo, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 May 04; Vol. 17 (5), pp. e0267901. Date of Electronic Publication: 2022 May 04 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Deep Learning*
Drug-Related Side Effects and Adverse Reactions*
Hand-Foot Syndrome*/diagnosis
Hand-Foot Syndrome*/etiology
Neoplasms*
Humans ; Natural Language Processing ; Quality of Life
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Practicality of STAT3 Gene Polymorphisms and Sorafenib Trough Concentration as Biomarkers for Sorafenib-Induced Hand-Foot Skin Reaction in Hepatocellular Carcinoma.
Autorzy:
Takatsuka, Hirokazu
Sugawara, Takato
Uchida, Masashi
Yamazaki, Shingo
Suzuki, Takaaki
Kanogawa, Naoya
Ogasawara, Sadahisa
Shiko, Yuki
Kawasaki, Yohei
Kato, Naoya
Ishii, Itsuko
Pokaż więcej
Źródło:
Journal of Clinical Pharmacy & Therapeutics. 8/19/2023, p1-9. 9p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Autorzy:
Dong SQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wang TM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang JB; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
He YQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xue WQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Wu ZY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yang DW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Cao LJ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Huang JW; School of Public Health, Sun Yat-sen University, Guangzhou, China.
Li XZ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhang PF; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zheng XH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jia WH; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.; School of Public Health, Sun Yat-sen University, Guangzhou, China.; Cancer Center of Guangzhou Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2021 Jul; Vol. 53 (3), pp. 724-732. Date of Electronic Publication: 2020 Dec 02.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Antimetabolites, Antineoplastic/*adverse effects
Capecitabine/*adverse effects
Colorectal Neoplasms/*drug therapy
Hand-Foot Syndrome/*genetics
Thymidylate Synthase/*genetics
3' Untranslated Regions/genetics ; Adult ; Aged ; Aged, 80 and over ; Asian People/genetics ; Colorectal Neoplasms/genetics ; Female ; Genetic Predisposition to Disease ; Hand-Foot Syndrome/epidemiology ; Humans ; Hydro-Lyases/metabolism ; Male ; Middle Aged ; Polymorphism, Single Nucleotide ; Thymidylate Synthase/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.
Autorzy:
Hiromoto S; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Kawashiri T; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan. .
Yamanaka N; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Kobayashi D; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Mine K; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Inoue M; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Uchida M; Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Osaka, 569-1094, Japan.
Shimazoe T; Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Apr 26; Vol. 11 (1), pp. 8964. Date of Electronic Publication: 2021 Apr 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Capecitabine/*adverse effects
Hand-Foot Syndrome/*drug therapy
Omeprazole/*pharmacology
Proton Pump Inhibitors/*pharmacology
Animals ; Capecitabine/pharmacology ; Disease Models, Animal ; Hand-Foot Syndrome/metabolism ; Hand-Foot Syndrome/pathology ; Mice ; Mice, Inbred ICR
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 2244

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies